ONCO · Onconetix, Inc.

Revenue fell sharply 78.9% to $21.5K from $101.6K in Q1 2025, primarily attributable to lower product sales from Proteomedix during the three months ended March 31, 2026. This decline reflects reduced customer demand and timing of orders compared to the prior year period, where purchase orders under master sales agreements or standard terms generated higher volumes. The drop underscores commercial challenges in Onconetix's diagnostics business, as lower sales volumes failed to cover fixed production and fulfillment costs, leading investors to question the trajectory of Proclarix commercialization efforts.

The Company reported a gross loss of -$1.7K versus prior year's $45.8K profit, with gross margin inverting to -7.7%. Cost of revenue exceeded revenue primarily due to shrunken sales base while certain production and fulfillment costs remained relatively fixed. These costs to fulfill contracts do not meet capitalization criteria and are expensed as incurred, amplifying the margin pressure in this low-revenue environment. This dynamic highlights operating leverage risks for a biotech with minimal revenue generation since inception.

Net income loss halved 50.7% to -$4.2M from -$8.5M, driving diluted EPS to -$6.71 from -$0.53—a -1,166% change reflecting share dilution dynamics. The narrower loss aligns with ongoing financial position risks, where the Company has generated only minimal revenue and anticipates substantial net losses ahead, potentially never achieving profitability.

Net cash provided by operating activities was -$2.1M, similar to -$2.0M prior year, indicating steady cash burn. Financial instruments like cash, inventory, accounts receivable, accounts payable, accrued liabilities, operating lease liabilities, and notes payable are carried at cost, approximating fair value due to their short-term nature. This stability in cash usage persists despite revenue weakness, emphasizing the need for capital to support operations as losses continue.